Kobayashi Pharmaceutical Co., Ltd.

As of June 30, 2026, Kobayashi Pharmaceutical Co., Ltd. carries a market capitalization of 2.22B, placing it among publicly traded companies globally. Its enterprise value stands at 1.91B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Kobayashi Pharmaceutical Co., Ltd.'s next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Kobayashi Pharmaceutical Co., Ltd. has 74.34M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Kobayashi Pharmaceutical Co., Ltd. maintains a current ratio of 3.28, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Kobayashi Pharmaceutical Co., Ltd.'s stock has gained approximately 35.57% over the past 52 weeks. The 50-day moving average sits at 34.98, while the 200-day moving average is 31.76.

As of June 30, 2026, Kobayashi Pharmaceutical Co., Ltd. holds 308.67M in cash and equivalents against 3.89M in total debt, resulting in a net debt position of -253.22M. Total book value stands at 1.13B, with working capital of 467.12M providing operational flexibility.

Kobayashi Pharmaceutical Co., Ltd.'s most recent stock split took place on June 28, 2016 with a 1:2 split ratio.